Advertisement
YOU ARE HERE: LAT HomeCollectionsSanofi Aventis Company
IN THE NEWS

Sanofi Aventis Company

FEATURED ARTICLES
BUSINESS
September 7, 2005 | From Bloomberg News
Sanofi-Aventis said U.S. regulators approved a long-acting version of sleep aid Ambien, which loses patent protection next year. The Food and Drug Administration approved Ambien CR for use in helping people both fall and stay asleep, Paris-based Sanofi said. The approval in both uses may help Sanofi protect Ambien sales from competition by Lunesta, introduced earlier this year by Sepracor Inc.
ARTICLES BY DATE
BUSINESS
December 13, 2008 | Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis won an appeals court ruling Friday that will help them block generic competition to the blood thinner Plavix, the world's No. 2 selling-drug, in the U.S. until 2011. Bristol-Myers and Sanofi said that as a result of the ruling by a three-judge panel of the U.S. Court of Appeals for the Federal Circuit in Washington, they will seek reimbursement from Canadian drug maker Apotex Inc.
Advertisement
BUSINESS
June 30, 2007 | From Times Wire Services
Sanofi-Aventis withdrew its application to gain U.S. approval for a weight loss drug after a meeting at which government advisors rejected the treatment on safety grounds. The French company said it would resubmit its Food and Drug Administration application for Acomplia later. The company is discussing with government regulators ways to improve its application.
BUSINESS
June 30, 2007 | From Times Wire Services
Sanofi-Aventis withdrew its application to gain U.S. approval for a weight loss drug after a meeting at which government advisors rejected the treatment on safety grounds. The French company said it would resubmit its Food and Drug Administration application for Acomplia later. The company is discussing with government regulators ways to improve its application.
BUSINESS
August 18, 2006 | From Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis won U.S. regulatory approval for the use of their blood thinner Plavix after severe heart attacks. The benefit to the drug makers may be limited because Apotex Inc. last week started marketing a cheaper copy of Plavix, the world's second-biggest-selling drug behind Pfizer Inc.'s Lipitor cholesterol pill. A U.S. court today will hear Sanofi and Bristol-Myers' request to bar Apotex's product. At stake is $6.3 billion in annual revenue.
BUSINESS
December 13, 2008 | Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis won an appeals court ruling Friday that will help them block generic competition to the blood thinner Plavix, the world's No. 2 selling-drug, in the U.S. until 2011. Bristol-Myers and Sanofi said that as a result of the ruling by a three-judge panel of the U.S. Court of Appeals for the Federal Circuit in Washington, they will seek reimbursement from Canadian drug maker Apotex Inc.
NATIONAL
June 30, 2006 | From Times Wire Reports
Sanofi-Aventis has put a stronger warning on its antibiotic Ketek after the deaths of four patients who took the drug and developed liver failure, U.S. regulators said. Liver failure was reported in eight other Ketek users, including one who required a liver transplant as a result, the Food and Drug Administration said. Twenty-three others developed less serious liver damage, the FDA said.
NATIONAL
December 15, 2006 | Ricardo Alonso-Zaldivar, Times Staff Writer
A Food and Drug Administration meeting to review whether a recently approved antibiotic carries an unacceptably high risk of liver failure raised questions Thursday about the credibility of the agency's internal decision-making. The antibiotic, Ketek, was approved in 2004 to treat pneumonia and other severe respiratory infections. It appeared promising as a weapon against microbes resistant to older antibiotics.
BUSINESS
December 9, 2006 | From the Associated Press
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
NATIONAL
December 15, 2006 | Ricardo Alonso-Zaldivar, Times Staff Writer
A Food and Drug Administration meeting to review whether a recently approved antibiotic carries an unacceptably high risk of liver failure raised questions Thursday about the credibility of the agency's internal decision-making. The antibiotic, Ketek, was approved in 2004 to treat pneumonia and other severe respiratory infections. It appeared promising as a weapon against microbes resistant to older antibiotics.
BUSINESS
December 9, 2006 | From the Associated Press
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
BUSINESS
August 18, 2006 | From Bloomberg News
Bristol-Myers Squibb Co. and Sanofi-Aventis won U.S. regulatory approval for the use of their blood thinner Plavix after severe heart attacks. The benefit to the drug makers may be limited because Apotex Inc. last week started marketing a cheaper copy of Plavix, the world's second-biggest-selling drug behind Pfizer Inc.'s Lipitor cholesterol pill. A U.S. court today will hear Sanofi and Bristol-Myers' request to bar Apotex's product. At stake is $6.3 billion in annual revenue.
NATIONAL
June 30, 2006 | From Times Wire Reports
Sanofi-Aventis has put a stronger warning on its antibiotic Ketek after the deaths of four patients who took the drug and developed liver failure, U.S. regulators said. Liver failure was reported in eight other Ketek users, including one who required a liver transplant as a result, the Food and Drug Administration said. Twenty-three others developed less serious liver damage, the FDA said.
BUSINESS
September 7, 2005 | From Bloomberg News
Sanofi-Aventis said U.S. regulators approved a long-acting version of sleep aid Ambien, which loses patent protection next year. The Food and Drug Administration approved Ambien CR for use in helping people both fall and stay asleep, Paris-based Sanofi said. The approval in both uses may help Sanofi protect Ambien sales from competition by Lunesta, introduced earlier this year by Sepracor Inc.
Los Angeles Times Articles
|